secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001104659-21-137472
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q3 revenue $1.6B (-1% YoY); adj. EPS $1.67; FY guidance narrowed; dividend $0.28
--------------------------------------------------------------------------------

- Revenue $1,600M, down 1% as-reported and 3% ex-FX YoY; net income from continuing ops $323M ($1.27 diluted EPS).
- Adjusted net income $424M ($1.67 diluted EPS); Adjusted EBITDA $636M (39.8% margin).
- Women's Health revenue $381M (-10% as-reported); Biosimilars +41%; Established Brands -6%.
- Board declares Q4 dividend $0.28/share, payable Dec 16, 2021, record Nov 22, 2021.
- Affirms FY guidance, narrows revenue range to $6.2B-$6.3B and Adj. EBITDA margin to 36.5%-37.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/0001104659-21-137472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465921137472/tm2131080d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-137472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer